

# SEQUENCE LISTING

<110> Gendaq Limited

<120> Screening System

<130> p3755

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 264

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic DNA

<220>

<221> CDS

<222> (1)..(264)

<400> 1

gca gaa gag aag cct ttt cag tgt cga atc tgc atg cgt aac ttc agc 48

Ala Glu Glu Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser

1 5 10 15

gat cgt agt agt ctt acc cgc cac acg agg acc cac aca ggc gag aag 96

Asp Arg Ser Ser Leu Thr Arg His Thr Arg Thr His Thr Gly Glu Lys

20 25 30

cct ttt cag tgt cga atc tgc atg cgt aac ttc agc agg agc gat aac 144

Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn

35 40 45

ctt acg aga cac cta agg acc cac aca ggc gag aag cct ttt cag tgt 192

Leu Thr Arg His Leu Arg Thr His Thr Gly Glu Lys Pro Phe Gln Cys

50 55 60

cga atc tgc atg cgt aac ttc agg caa gct gat cat ctt caa gag cac 240

Arg Ile Cys Met Arg Asn Phe Arg Gln Ala Asp His Leu Gln Glu His

65 70 75 80

cta aag acc cac aca ggc gag aag  
Leu Lys Thr His Thr Gly Glu Lys  
85

264

<210> 2

<211> 88

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Synthetic DNA

<400> 2

Ala Glu Glu Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser  
1 5 10 15

Asp Arg Ser Ser Leu Thr Arg His Thr Arg Thr His Thr Gly Glu Lys  
20 25 30

Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn  
35 40 45

Leu Thr Arg His Leu Arg Thr His Thr Gly Glu Lys Pro Phe Gln Cys  
50 55 60

Arg Ile Cys Met Arg Asn Phe Arg Gln Ala Asp His Leu Gln Glu His  
65 70 75 80

Leu Lys Thr His Thr Gly Glu Lys  
85

# SEQUENCE LISTING

<110> Gendaq Limited

<120> Screening System

<130> 674538-2003

<150> PCT/GB99/03730

<151> 1999-11-09

<150> GB9824544.2

<151> 1998-11-09

<160> 16

<170> PatentIn version 3.0

<210> 1

<211> 264

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_structure

<222> (1)..(264)

<223> sequence coding for a zinc finger protein

<400> 1

gcagaagaga agccttttca gtgtcgaatc tgcattgcga acttcagcga tcgtagtagt 60

cttaccgcgc acacgaggac ccacacaggc gagaagcctt ttcagtgtcg aatctgcatg 120

cgtaacttca gcaggagcga taaccttacg agacacctaa ggacccacac aggcgagaag 180

cctttttcagt gtcgaatctg catgcgtaac ttcaggcaag ctgatcatct tcaagagcac 240

ctaaagaccc acacaggcga gaag 264

<210> 2

<211> 88

<212> PRT

<213> Artificial Sequence

<220>

<221> ZN\_FING

<222> (1)..(88)

<223> protein sequence encoding a zinc-finger domain

<400> 2

Ala Glu Glu Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser

1

5

10

15

Asp Arg Ser Ser Leu Thr Arg His Thr Arg Thr His Thr Gly Glu Lys  
20 25 30

Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn  
35 40 45

Leu Thr Arg His Leu Arg Thr His Thr Gly Glu Lys Pro Phe Gln Cys  
50 55 60

Arg Ile Cys Met Arg Asn Phe Arg Gln Ala Asp His Leu Gln Glu His  
65 70 75 80

Leu Lys Thr His Thr Gly Glu Lys  
85

<210> 3

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<221> VARIANT

<222> (1)..(31)

<223> 'X' can be any amino acid as described in the specification

<400> 3

Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa Xaa His  
20 25 30

<210> 4

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<221> VARIANT

<222> (1)..(31)

<223> 'X' can be any amino acid as described in the specification

<400> 4

Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Cys  
20 25 30

<210> 5

<211> 24

<212> PRT

<213> Artificial Sequence

<400> 8

Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Lys Ser Asp  
1 5 10 15

Leu Val Lys His Gln Arg Thr His Thr Gly  
20 25

<210> 9

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> ZN\_FING

<222> (1)..(29)

<223> zinc finger consensus structure

<400> 9

Pro Tyr Lys Cys Ser Glu Cys Gly Lys Ala Phe Ser Gln Lys Ser Asn  
1 5 10 15

Leu Thr Arg His Gln Arg Ile His Thr Gly Glu Lys Pro  
20 25

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(6)

<223> leader peptide

<400> 10

Met Ala Glu Glu Lys Pro  
1 5

<210> 11

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(4)

<223> smallest unit of stalling polypeptide sequence

<400> 11

Ala Ala Val Pro

1

<210> 12

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(24)

<223> linker sequence followed by the stalling polypeptide sequence

<400> 12

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
1 5 10 15

Gly Gly Gly Ser Ala Ala Val Pro  
20

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> promoter

<222> (1)..(23)

<223> bacteriophage T7 RNA polymerase promoter sequence

<400> 13

taatacgact aactataggg aga

23

<210> 14

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<221> RBS

<222> (1)..(6)

<223> bacteriophage T7, gene 10 ribosome binding site

<400> 14

aaggag

6

<210> 15

<211> 18

<212> DNA

<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(18)  
<223> DNA sequence encoding the ribosome stalling peptide sequence

<400> 15  
atggttaaaa cagataaa

18

<210> 16  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<221> PEPTIDE  
<222> (1)..(6)  
<223> ribosome stalling peptide sequence

<400> 16

Met Val Lys Thr Asp Lys  
1 5